iRhythm Technologies, Inc. (NASDAQ:IRTC) Shares Purchased by Champlain Investment Partners LLC

Champlain Investment Partners LLC raised its holdings in iRhythm Technologies, Inc. (NASDAQ:IRTC - Free Report) by 8.9% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 726,262 shares of the company's stock after acquiring an additional 59,161 shares during the period. Champlain Investment Partners LLC owned 2.32% of iRhythm Technologies worth $65,487,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Vanguard Group Inc. grew its holdings in iRhythm Technologies by 0.6% in the 4th quarter. Vanguard Group Inc. now owns 3,136,370 shares of the company's stock valued at $282,806,000 after buying an additional 18,442 shares during the period. State Street Corp increased its position in iRhythm Technologies by 1.3% during the third quarter. State Street Corp now owns 908,843 shares of the company's stock worth $67,473,000 after purchasing an additional 11,992 shares during the last quarter. Geode Capital Management LLC raised its stake in iRhythm Technologies by 0.7% during the third quarter. Geode Capital Management LLC now owns 733,308 shares of the company's stock worth $54,451,000 after purchasing an additional 5,423 shares during the period. Allspring Global Investments Holdings LLC boosted its holdings in shares of iRhythm Technologies by 9.6% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 570,048 shares of the company's stock valued at $50,991,000 after purchasing an additional 50,075 shares during the last quarter. Finally, Bessemer Group Inc. grew its stake in shares of iRhythm Technologies by 111.7% during the 4th quarter. Bessemer Group Inc. now owns 568,007 shares of the company's stock valued at $51,217,000 after buying an additional 299,726 shares during the period.

iRhythm Technologies Stock Performance

iRhythm Technologies stock traded up $1.76 during mid-day trading on Tuesday, reaching $100.39. The company's stock had a trading volume of 83,153 shares, compared to its average volume of 457,784. The company has a current ratio of 6.27, a quick ratio of 6.12 and a debt-to-equity ratio of 9.00. iRhythm Technologies, Inc. has a twelve month low of $55.92 and a twelve month high of $128.52. The business has a 50 day moving average price of $105.20 and a 200-day moving average price of $93.86. The firm has a market cap of $3.15 billion, a price-to-earnings ratio of -27.58 and a beta of 1.45.

iRhythm Technologies (NASDAQ:IRTC - Get Free Report) last announced its quarterly earnings data on Thursday, February 20th. The company reported $0.01 earnings per share for the quarter, beating analysts' consensus estimates of ($0.29) by $0.30. iRhythm Technologies had a negative net margin of 19.14% and a negative return on equity of 118.83%. The business had revenue of $164.33 million during the quarter, compared to the consensus estimate of $158.30 million. Sell-side analysts predict that iRhythm Technologies, Inc. will post -1.98 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

IRTC has been the subject of several research analyst reports. Needham & Company LLC upped their price target on iRhythm Technologies from $125.00 to $138.00 and gave the stock a "buy" rating in a research note on Friday, February 21st. Truist Financial lifted their price target on shares of iRhythm Technologies from $111.00 to $145.00 and gave the company a "buy" rating in a research report on Friday, February 21st. Oppenheimer raised their target price on shares of iRhythm Technologies from $105.00 to $120.00 and gave the company an "outperform" rating in a research note on Wednesday, January 8th. StockNews.com upgraded iRhythm Technologies from a "sell" rating to a "hold" rating in a report on Monday, February 24th. Finally, The Goldman Sachs Group boosted their price target on iRhythm Technologies from $91.00 to $124.00 and gave the stock a "neutral" rating in a research report on Monday, February 24th. Three investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. Based on data from MarketBeat, iRhythm Technologies presently has an average rating of "Moderate Buy" and a consensus price target of $119.73.

iRhythm Technologies Profile

iRhythm Technologies, Inc, a digital healthcare company, engages in the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. It offers Zio services, an ambulatory monitoring solution, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services.